Deutsche Bank AG Buys 16,445 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Deutsche Bank AG raised its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 23.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 85,227 shares of the medical instruments supplier's stock after buying an additional 16,445 shares during the quarter. Deutsche Bank AG owned about 0.15% of Merit Medical Systems worth $8,243,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MMSI. Vanguard Group Inc. raised its holdings in shares of Merit Medical Systems by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,648,659 shares of the medical instruments supplier's stock worth $643,058,000 after acquiring an additional 63,314 shares during the period. FMR LLC raised its stake in shares of Merit Medical Systems by 31.6% in the 4th quarter. FMR LLC now owns 2,076,439 shares of the medical instruments supplier's stock valued at $200,833,000 after purchasing an additional 499,193 shares during the period. Fuller & Thaler Asset Management Inc. raised its stake in shares of Merit Medical Systems by 2.3% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,633,246 shares of the medical instruments supplier's stock valued at $157,968,000 after purchasing an additional 36,489 shares during the period. Invesco Ltd. lifted its stake in Merit Medical Systems by 8.3% in the 4th quarter. Invesco Ltd. now owns 1,535,468 shares of the medical instruments supplier's stock valued at $148,510,000 after acquiring an additional 118,142 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Merit Medical Systems by 12.8% in the fourth quarter. Northern Trust Corp now owns 750,936 shares of the medical instruments supplier's stock valued at $72,631,000 after purchasing an additional 85,483 shares during the last quarter. Institutional investors and hedge funds own 99.66% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Robert W. Baird lowered their price target on Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Raymond James dropped their price target on shares of Merit Medical Systems from $116.00 to $108.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Barrington Research dropped their target price on shares of Merit Medical Systems from $111.00 to $103.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Piper Sandler cut their target price on Merit Medical Systems from $116.00 to $112.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Finally, Needham & Company LLC raised their price target on shares of Merit Medical Systems from $100.00 to $108.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $108.67.

Merit Medical Systems Stock Up 0.7%

NASDAQ:MMSI traded up $0.71 during mid-day trading on Tuesday, hitting $98.81. 926,676 shares of the company's stock were exchanged, compared to its average volume of 517,657. Merit Medical Systems, Inc. has a one year low of $80.02 and a one year high of $111.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The business has a fifty day moving average price of $96.74 and a 200 day moving average price of $100.60. The company has a market cap of $5.84 billion, a PE ratio of 48.44, a P/E/G ratio of 2.34 and a beta of 0.70.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $0.86 EPS for the quarter, topping the consensus estimate of $0.75 by $0.11. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The business had revenue of $355.35 million for the quarter, compared to analyst estimates of $352.57 million. During the same quarter in the previous year, the firm posted $0.77 earnings per share. Merit Medical Systems's quarterly revenue was up 9.8% on a year-over-year basis. Equities analysts predict that Merit Medical Systems, Inc. will post 3.37 EPS for the current year.

Insider Transactions at Merit Medical Systems

In other Merit Medical Systems news, insider Brian G. Lloyd sold 25,000 shares of Merit Medical Systems stock in a transaction on Friday, February 28th. The shares were sold at an average price of $99.50, for a total value of $2,487,500.00. Following the sale, the insider now directly owns 38,993 shares in the company, valued at approximately $3,879,803.50. The trade was a 39.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director F. Ann Millner sold 21,250 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $96.47, for a total transaction of $2,049,987.50. Following the transaction, the director now owns 34,543 shares in the company, valued at $3,332,363.21. The trade was a 38.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 130,382 shares of company stock worth $13,189,508. Corporate insiders own 3.20% of the company's stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.